



State of Vermont
Department of Vermont Health Access
NOB 1 South, 280 State Drive
Waterbury, VT 05671-1010

Agency of Human Services
[Phone] 802-879-5900
[Fax] 802-241-0268

December 28, 2020

****Important Changes to Coverage for Taltz****

Dear Medicaid Provider,

Effective 1/1/21, Taltz® (ixekizumab) will be moving to preferred status on the Department of Vermont Health Access (DVHA) Preferred Drug List (PDL), after clinical criteria are met. Taltz® is a humanized interleukin-17A antagonist indicated for the treatment of patients ages 6 years or older with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, and adults with active ankylosing spondylitis. Cosentyx® (secukinumab) will be moving to non-preferred status due to an increase in net cost to the Vermont Medicaid program. Please consider transitioning your Cosentyx® patient(s) to Taltz®, if clinically appropriate. ALL current prior authorizations for Cosentyx® will remain active through the expiration date specified on the Notice of Decision. If you feel it is not appropriate for your patient(s) to change therapy, please indicate on the PA renewal, and Cosentyx® will be re-authorized.

We continually monitor the net costs of these medications and periodically adjust the PDL if new or more cost-effective products become available. For questions, please contact the Change Healthcare Pharmacy Help Desk at 1-844-679-5362. Vermont providers can also send inquiries via email to **PBA_VTHelpdesk@changehealthcare.com**. Thank you for your continued support of Vermont's clinical pharmacy programs.

Nancy J. Hogue, BS, Pharm.D.

Director of Pharmacy Services